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Background There is a lack of data on the effects of angiotensin-receptor blocker and diuretic combinations on ambulatory blood pressure (ABP) in hypertensive patients with additional cardiovascular risk factors.
Methods In a randomized, double-blind trial, the effects on 24-h ABP of the combination valsartan 160 mg od and hydrochlorothiazide 25 or 12.5 mg during 24 weeks of therapy were compared with the effects of amlodipine 10 mg monotherapy (group A10) in 474 stage-II hypertensive patients with additional cardiovascular risk factors. After a two-week single-blind placebo run-in period, patients were randomized to receive valsartan 160 mg od or amlodipine 5 mg od. At week 4, HCTZ 12.5 mg (group V160/HCTZ12.5) and 25 mg (group V160/HCTZ25) were added to the valsartan groups and in the A10 patients the amlodipine dose was force-titrated to 10 mg od.
Results All three treatments reduced 24-h BP as well as night-time and daytime BP levels from baseline. Twentyfour hour systolic blood pressure (SBP) was reduced by 15.9 ± 1.0 mmHg (least-squares mean change ± SE), 19.3 ± 1.0 mmHg and 16.1 ± 1.1 mmHg in the V160/ HCTZ12.5, V160/HCTZ25 and A10 groups, respectively and 24-h diastolic blood pressure (DBP) was reduced by 9.3 ± 0.6 mmHg, 11.4 ± 0.6 mmHg and 9.6 ± 0.7 mmHg in the three groups. The differences between the V160/HCTZ25 group and the A10 group were significant (p < 0.05) for the changes in 24-h systolic BP as well as for changes in daytime systolic BP and night-time diastolic BP. Control rates defined as ABPM r 130/80 mmHg were: 48.4%, 60.8% and 50.9% in the V160/HCTZ12.5, V160/25 and A10 groups, respectively. The differences in control rates between the V160/HCTZ25 group and the other two treatment groups were significant at p < 0.05.
Conclusions
The fixed-dose combination of valsartan 160 mg + HCTZ 25 mg od is an attractive therapeutic option measured on the effects on 24-h ABPM, night-time and daytime BP reduction and control rates in hypertensive patients at additional cardiovascular risk. Blood Press Monit 10:85-91 c 2005 Lippincott Williams & Wilkins.
Introduction
Ambulatory blood pressure measurement (ABPM) is considered an important adjunct to conventional clinic blood pressure (BP) measurement [1] . Although the exact reasons for the limited relationship between the two modes of BP measurements are debated [2] , ABPM appears to correlate with target organ damage more closely than does office BP [3, 4] and to be a better predictor of cardiovascular risk than office BP both in general populations and in hypertensive patients [5, 6] . Thus, current hypertension guidelines recommend considering ABPM to obtain valuable information in addition to clinic BP measurements [1, 7] .
From this additional prognostic value of ABPM follows that the effects of antihypertensive treatments on ABPM should be assessed in addition to office BP and a large number of recent trials have included ABPM sub-studies. Although treatments may have highly similar effects on overall clinic BP reductions, this may mask relevant differences in effects on circadian BP variations, BP load and so forth, all of which may influence overall risk.
The commonly used combination therapies of angiotensin-receptor blockers (ARBs) and diuretics are well know to be safe and efficacious as measured on effects of office BP but their effect on ABPM are less well described. It was shown recently [8] that a combination of valsartan 160 mg and hydrochlorothiazide (HCTZ) 12.5 mg od achieves significantly greater reductions in average BP over a 24 h period than combination treatments based on amlodipine 10 mg od in elderly patients with isolated systolic hypertension (ISH), although the treatments were equal in their effects on systolic BP. The greater effects on ABPM with the valsartan and HCTZ combination therapy were due to a greater reduction in systolic BP in responders, mainly during the daytime. However, although there have been some studies on combination therapies with ARBs and/or ACE inhibitors and HCTZ in risk populations [9, 10] there is a lack of data on the effects of ARB and diuretic combinations on ABPM, particularly in hypertensive patients with additional cardiovascular risk factors.
The VAST study (Valsartan/HCTZ versus Amlodipine in STage II hypertensive patients with additional cardiovascular risk factors) [11] investigated the BP-lowering effects of valsartan with HCTZ in hypertensive patients with at least one additional cardiovascular risk factor. The main clinical efficacy and tolerability results have been published. The current communication describes the results of the VAST sub-study on the effects on 24 h ABPM.
Methods
This was a sub-study of the multicentre, randomized, double-blind, active-controlled, three-arm VAST study. Previously treated and untreated male or female patients Z 18 years old with a proven medical history of moderate hypertension were included. For untreated patients the inclusion requirement was a mean sitting systolic BP (MSSBP) Z 160 mmHg at all pre-randomization visits. Patients on current anti-hypertensive treatment should be uncontrolled, defined as BP Z 140/90 and r 160/ 95 mmHg at Visit 1. Patients should have at least one of the following cardiovascular risk factors: Obesity with a body mass index (BMI) over 30 kg/m 2 ; controlled type II diabetes mellitus; receiving current treatment with lipidlowering drugs; total cholesterol value > 240 mg/dL, and/ or low-density lipoprotein (LDL) cholesterol > 160 mg/ dL if untreated; myocardial infarction or coronary artery bypass graft or percutaneous transluminal coronary angioplasty more than one year ago; stroke or transient ischaemic cerebral attack more than one year ago; or aged Z 65 years. The study was conducted in accordance with Good Clinical Practices and the Declaration of Helsinki and the local Ethics Committees approved the protocol. All patients gave their written informed consent.
After a two-week single-blind placebo run-in period, patients were randomized in a 1:1:1 ratio to receive: valsartan 160 mg od (two groups) or amlodipine 5 mg od (group A10). At Week 4, HCTZ 12.5 mg (group V160/ HCTZ12.5) or 25 mg (group V160/HCTZ25) were added to the therapy in the valsartan groups and in the A10 patients the amlodipine dose was force-titrated to 10 mg od. Patients were followed-up for a total of 24 weeks.
The ABPM sub-study was carried out at 47 of the centres participating in VAST. Centres were invited to take part only if they had proven experience in ABP measurement and ABP was measured on all patients at all centres included. Ambulatory BP measurements were performed at baseline (Visit 3) and at study end (Visit 7) ( Figure 1 ). Thus, in addition to the visits scheduled in the main study, the patients attending centres performing ABPM required an additional two visits: in the morning of the day before Visit 3 (Day-1) and in the morning of the day before the final Visit 7.
All ABPM was performed over a working day (Monday through Friday). Daytime was defined as the period from 06:00 h to 22:00 h, and night-time from 22:00 h to 06:00 h. Readings were taken every 15 min during the day and every 30 min during the night, with each recording starting in the morning (between 07:00 h and 10:00 h) immediately before taking the study drug and ending after 24 h of recording. The patients were instructed to avoid strenuous physical exercise and to remain still, with the arm extended at the time of the measurements. Ambulatory BP monitoring was performed with an oscillometric Spacelabs 90202 or 90207 equipment (Spacelabs, Redmond, Washington, USA) or with similar devices validated according to international guidelines [12, 13] . Before applying the ABPM device the investigator performed three office BP measurements. Blood pressure was measured three times by the ABPM device. Acceptable accuracy was defined as less than 5 mmHg difference between the mean office diastolic BP and the mean device diastolic BP; if differences were greater the device was repositioned and the three measurements repeated. A recording was accepted if it covered 24 h with at least 75% of measurements, not more than two consecutive hours of measurements were missing and data were available for hours 23 and 24 post-dose. Single BP measurements were considered invalid if systolic blood pressure (SBP) fell outside the range of 90-240 mmHg, if diastolic blood pressure (DBP) was outside 50-140 mmHg, if the DBP reading was greater than the preceding or subsequent SBP reading, if the pulse pressure fell outside the range of 20-100 mmHg or if heart rate was outside the range of 40-125 bpm.
The following parameters were evaluated in the ABPM population: mean 24 h SBP and DBP (calculated by averaging the patient's available hourly means); daytime and night-time mean, diurnal and nocturnal systolic and diastolic load (defined as the percentages of SBP readings exceeding 130 mmHg and the percentages of DBP readings exceeding 85 mmHg, respectively), nocturnal fall (calculated as [(mean diurnal BP -mean nocturnal BP)/mean diurnal BP]*100), overall responder rates (defined as 24 h SBP < 140 mmHg, or Z 20 mmHg reduction from baseline in mean 24 h SBP and mean 24 h DBP < 90 mmHg, or a reduction of Z 10 mmHg in mean 24 h DBP from baseline), control rates (24 h BP r 130/ 80 mmHg) as well as smoothness index (calculated as average hourly change between baseline and study end/ standard deviation of the hourly changes).
The change in ambulatory BP was analyzed using analysis of covariance with treatment, centre, and previously treated with as fixed factors and baseline measurement as covariate.
The adjusted mean differences and 95% confidence intervals are presented. Control and responder rates were analyzed by logistic regression with treatment, patients with ISH (yes/no) at baseline and previously treated (yes/ no) at baseline as factors. Point estimates along with 95% confidence intervals (Wald confidence limits) were calculated for the odds ratios of combination treatment versus monotherapy.
Results
The intent-to-treat population comprised 474 patients, 157 of whom received valsartan 160 mg plus HCTZ 12.5 mg, 158 valsartan 160 mg with HCTZ 25 mg and 159 amlodipine 10 mg od. The patient groups were well matched at baseline ( Table 1) . As in the overall VAST population, approximately two-thirds of the patients were previously treated for hypertension. A total of 142 (90.4%) of patients completed the study in the V160/HCTZ12.5, compared with 146 patients (91.8%) in the V160/HCTZ25 group and 112 (70.4%) in the A10 group.
All three treatments reduced SBP and DBP from baseline. Reductions were seen in 24 h BP as well as in night-time and daytime BP levels. Changes were significantly greater in the V160/HCTZ25 group than in the other two groups and there was a dose-related increase in efficacy between the V160/HCTZ12.5 and V160/HCTZ25 groups. Twenty-four hour SBP was reduced by 15.9 ± 1.0 mmHg (least-squares mean change ± SE), 19.3 ± 1.0 mm Hg and 16.1 ± 1.1 mmHg in the V160/HCTZ12.5, V160/HCTZ25 and A10 groups, respectively (Figure 1 and 2A) and 24 h DBP was reduced by 9.3 ± 0.6 mmHg, 11.4 ± 0.6 mmHg and 9.6 ± 0.7mmHg in the three groups ( Figure 3A) . Daytime SBP was reduced by 16.2 ± 1.0 mmHg, 19.6 ± 1.0 mmHg, and 16.3 ± 1.1 mmHg in the V160/HCTZ12.5, V160/ HCTZ25, and A10 groups, respectively (Figure 1 and  2B ). Night-time SBP was reduced by 15.2 ± 1.2 mmHg, 18.6 ± 1.2 mmHg and 15.4 ± 1.3 mmHg, in the three groups, respectively (Figure 1 and 2C) . Daytime DBP reductions were 9.5 ± 0.7 mmHg, 11.6 ± 0.7 mmHg and 10.1 ± 0.7 mmHg ( Figure 3B ) and night-time DBP reductions 8.8 ± 0.7 mmHg, 10.8 ± 0.7 mmHg and 8.8 ± 0.8 mmHg in the V160/HCTZ12.5, V160-HCTZ25 and A10 groups, respectively ( Figure 3C ). The differences between the V160/HCTZ25 group and the A10 group were significant (p < 0.05) for the changes in 24 h systolic BP, changes in daytime systolic BP and the changes in night-time diastolic BP. The other differences were of borderline significance (0.05 < p < 0.06). The differences between the V160/HCTZ12.5 and the A10 groups did not reach statistical significance for any of the variables monitored.
Response rates were high in all treatment groups. Rates of systolic response were 85.8%, 90.8% and 92.5% in the V160/HCTZ12.5, V160/HCTZ25 and A10 groups, re-spectively. Diastolic response rates were 96.1%, 100% and 100% in the three treatment groups (all between-groups differences not significant). With the more stringent definition of ABPM control as r 130/80 mmHg, there were significant differences between the treatment groups. Control rates at this level were markedly greater in the V160/HCTZ25 group than in the other two treatment groups: 48.4%, 60.8% and 50.9% in the V160/HCTZ12.5, V160/25 and A10 groups, respectively ( Figure 4 ). The differences in control rates between the V160/HCTZ25 group and the other two treatment groups were significant at p < 0.05.
All treatments reduced circadian BP and the greater effects in the V160/HCTZ25 group were not restricted to SBP ( Figure 5 ) or DBP ( Figure 6 ), nor to daytime or night-time BP. The differences between treatments on the effects on circadian BP were further reflected in differences in the effects on diurnal and nocturnal SBP loads. Systolic diurnal and systolic nocturnal loads were improved from baseline with all treatments but the improvement was greater in the V160/HCTZ25 group (Table 2 ) than in the other two treatment groups. For diastolic diurnal and nocturnal load there was a trend towards greater improvement in the V160/HCTZ25 group (Table 2 ) but this did not reach statistical significance.
There appeared to be differences in the effects on the 06:00 h to noon BP with the different treatments, with a greater reduction in the V160/HCTZ25 group than in the other groups. The reduction in SBP was 2.7 ± 1.6 mmHg greater in this group than in the A10 group. This greater reduction was of borderline significance (95% confidence interval for between-group comparison -0.50:5.93 mmHg, p = 0.098). Differences in 06:00 h to noon DBP between treatment groups were smaller (1.28 ± 1.03 mmHg, p = 0.22).
Tolerability in the ABPM sub-study patient groups was not significantly different from what was seen in the overall VAST study. Most suspected drug-related adverse events (AEs) occurred with very low frequency (< 2%) and were mild with no differences between the treatment groups. The only AE with greater than 2% occurrence was leg oedemas, which occurred several-fold more frequently in the A10 group (7.6%, 6.3% and 39.6% in the V160/HCTZ12.5, V160/HCTZ25 and A10 groups, respectively). Dizziness was reported in three patients (1.9%) in the V160/HCTZ25 group. Only one case (0.6%) of hyperkalaemia occurred (in the V160/HCTZ25 group). Discontinuation rates were greater in the group receiving amlodipine, five patients (3.2%); and five patients (3.1%) discontinued because of adverse events in the V160/ HCTZ12.5 and the V160/HCTZ25 groups, respectively, compared with 32 patients (22.6%) in the A10 group.
Discussion
The data presented here, from the ABPM sub-study of the VAST trial, show significantly greater reductions in BP with the fixed-dose combination of valsartan 160 mg and HCTZ 25 mg od than with amlodipine 10 mg od monotherapy or with the combination valsartan 160 mg with HCTZ 12.5 mg od. The differences between treatment groups were seen consistently on all variables monitored: 24 h SBP/DBP, night-time and daytime SBP/ DBP. Systolic BP load was reduced to a significantly greater extent with the valsartan 160 mg and HCTZ 25 mg combination than with the other treatments. Further, using a definition of ABPM control as < 130/ 80 mmHg, a significantly larger proportion of patients (60.8%) were controlled with the valsartan 160 mg and HCTZ 25 mg combination than with amlodipine 10 mg monotherapy (50.9%). There were no significant differences between the combination valsartan 160 mg and HCTZ 12.5 mg and amlodipine 10 mg in terms of efficacy, ABPM control rates or BP load.
With an intent-to-treat population of 474 patients, this was one of the largest 24 h ABPM studies conducted. However, the limitation should be acknowledged that this was a sub-study and the patient population was significantly smaller than the overall population. Nevertheless, we believe the data to be reliable, since the study was designed prospectively and all participating centres measured ABPM for all patients, greatly reducing the risk of bias.
Further, there were no significant differences between the populations, or between the sub-study population and the overall VAST population at baseline. The variability of the results was minor and the differences between the treatment groups appear significant and reliable.
The findings for valsartan 160 mg with HCTZ 12.5 mg and amlodipine 10 mg in VASTextend the findings from a study in a different set of patients by Palatini et al., [8] .
The current populations were twice as large as those studied by Palatini et al., and the patient groups were selected for the presence of additional cardiovascular risk factors whereas the patients in the study by Palatini et al., were elderly (mean age 69 years versus 60 years in VAST) selected for the presence of ISH and not for any other risk factors. Further, the Palatini study started at a valsartan dose of 80 mg od, whereas in VAST, the starting dose was 160 mg od. Thus the results are complementary and the additional efficacy seen with valsartan 160 mg with HCTZ 25 mg are indicative of the scope for greater efficacy with higher doses of the diuretic in combination with the ARB.
The relative merits of office BP and ABPM are still subject to some controversy [2] but there is a broad consensus that these two approaches to BP evaluations are complementary, not alternative tools for assessing cardiovascular risk. Reductions in ABPM appear to reflect antihypertensive treatment effects more accurately than office BP because of the absence of 'white-coat' [14] and placebo [15] effects and the reproducibility of results over time may be better [16] although increasing the number of office measurements may reduce the differences between the methods. Ambulatory BPM has also been shown to be useful in stratifying the risk in patients with refractory hypertension according to office BP measurements [17] . Clement and colleagues recently found elevated ABP, systolic or diastolic, to be predictive of cardiovascular events in treated hypertensive patients even after adjusting for other risk factors including office BP [18] .
The patients in VAST were selected for hypertension, either untreated (MSSBP Z 160 mmHg) or treated but uncontrolled (BP r 160/95 mmHg), and the presence of at least one additional cardiovascular risk factor. Such patients are at 'moderate added risk' according to current guidelines [1] and drug treatment is mandated to bring BP under control. Combination therapies are considered as one option among several in these patients. However, recent trials [19] have shown that treated but insufficiently controlled patients with hypertension and additional cardiovascular risk factors are at higher cardiovascular risk than previously estimated and that aggressive combination therapies may have a use in patients at an apparently lower level of risk than currently recommended. This adds to both the urgency and the difficulty of bringing risk populations to within acceptable BP ranges. It is highly promising that the valsartan 160 mg and HCTZ 25 mg combination brought BP in 60.8% of patients to a target of 130/80 mmHg after 24 weeks, the more so given that the majority of patients were previously treated with insufficient success. However, it should be noted that 24 h ABPM values tend to be lower than clinic BP readings [20] and an ABPM of 130/ 80 mmHg has not been validated as a treatment target comparable to 140/90 mmHg clinic BP.
The recently completed VALUE trial [19] reported differences in BP lowering between a valsartan-based treatment regimen and an amlodipine-based regimen. In VALUE most patients received combination therapies with mainly HCTZ. Although no ABPM data from VALUE are available, the VAST study indicates that higher starting doses of valsartan and possibly a washout period would have produced markedly different BP results. In VALUE, the starting dose of valsartan was 80 mg, which might be lower than optimal. As the VALUE investigators speculate, a 320 mg valsartan dose, as available in the USA, might have been the best maximal dose. Further, 92% of patients in VALUE were previously treated and were rolled over directly to study treatment (monotherapy), which may have affected the response.
The VAST data indicate that good BP control is achievable at a low tolerability cost with adequate doses of valsartan and HCTZ in hypertensive patients with additional cardiovascular risk factors.
The use of BP load as an indication of hypertensive burden has been propagated for many years as a clinically meaningful indicator based on the data from ABPM [21] . The concept of load is based on the fact that in mild-tomoderate hypertensive patients, BP is not elevated all the time during a 24 h period. Thus, BP load, which measures the percentage of readings above the threshold, is a measure of the time a hypertensive patient is actually suffering from elevated BP. Thus, the greater reduction in systolic BP load with valsartan 160 mg and HCTZ 25 mg over amlodipine 10 mg indicates that not only BP, but the time spent at risk during a 24 h period, is lower with the high-dose combination treatment.
Tolerability in the VAST ABPM sub-study reflected the results in the overall study, with the only frequent AE, leg oedema, four-fold more frequent in patients treated with amlodipine than in those receiving valsartan with HCTZ. There were no increases in AEs in the V160/HCTZ25 group compared with the group on the lower dose of the diuretic. Such low AE rates are probably one reason for the low rates of discontinuations seen with the valsartan and HCTZ combination therapies, the VAST overall population, as well as in other studies [22, 23] .
In summary, the VAST ABPM sub-study adds to the results of the main VAST study and shows the fixed-dose combination of valsartan 160 mg with HCTZ 25 mg od to be an attractive therapeutic option measured on the effects on 24 h ABPM, night-time and daytime BP reduction, control rates and BP load, in hypertensive patients at additional cardiovascular risk. It would be interesting to assess the long-term benefits and the predictive value of the study variables in a specifically designed trial.
